MTCR
NASDAQMetacrine Inc.
Metacrine Inc. (MTCR) is a Medicinal Chemicals and Botanical Products company listed on NASDAQ. There were no new wire items for MTCR in the last 30 days. The most recent was published Mar 24, 2023.
Latest news
25 items- SECSEC Form 15-12G filed by Metacrine Inc.15-12G - Metacrine, Inc. (0001634379) (Filer)
- SECMetacrine Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Leadership Update, Submission of Matters to a Vote of Security Holders8-K - Metacrine, Inc. (0001634379) (Filer)
- INSIDERSEC Form 4 filed by Klassen Preston4 - Metacrine, Inc. (0001634379) (Issuer)
- SECSEC Form S-8 POS filed by Metacrine Inc.S-8 POS - Metacrine, Inc. (0001634379) (Filer)
- SECSEC Form S-8 POS filed by Metacrine Inc.S-8 POS - Metacrine, Inc. (0001634379) (Filer)
- SECMetacrine Inc. filed SEC Form 8-K: Leadership Update8-K - Metacrine, Inc. (0001634379) (Filer)
- SECMetacrine Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets8-K - Metacrine, Inc. (0001634379) (Filer)
- SECSEC Form EFFECT filed by Metacrine Inc.EFFECT - Metacrine, Inc. (0001634379) (Filer)
- SECSEC Form 25-NSE filed by Metacrine Inc.25-NSE - Metacrine, Inc. (0001634379) (Subject)
- 13D/GSEC Form SC 13G/A filed by Metacrine Inc. (Amendment)SC 13G/A - Metacrine, Inc. (0001634379) (Subject)
- SECSEC Form DEF 14A filed by Metacrine Inc.DEF 14A - Metacrine, Inc. (0001634379) (Filer)
- SECMetacrine Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Events That Accelerate or Increase a Direct Financial Obligation8-K - Metacrine, Inc. (0001634379) (Filer)
- 13D/GSEC Form SC 13G/A filed by Metacrine Inc. (Amendment)SC 13G/A - Metacrine, Inc. (0001634379) (Subject)
- SECMetacrine Inc. filed SEC Form 8-K: Leadership Update8-K - Metacrine, Inc. (0001634379) (Filer)
- NEWS12 Health Care Stocks Moving In Wednesday's After-Market SessionGainers HTG Molecular Diagnostics (NASDAQ:HTGM) shares moved upwards by 33.0% to $6.01 during Wednesday's after-market session. This security traded at a volume of 323.6K shares come close, making up 21.6% of its average volume over the last 100 days. The company's market cap stands at $6.1 million. Lannett (NYSE:LCI) shares rose 15.74% to $0.62. The market value of their outstanding shares is at $26.2 million. As per the press release, Q2 earnings came out today. Align Tech (NASDAQ:ALGN) shares rose 15.03% to $325.0. At the close, Align Tech's trading volume reached 121.5K shares. This is 11.8% of its average volume over the last 100 days. The company's market cap stands at $25.3 billion
- SECMetacrine Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - Metacrine, Inc. (0001634379) (Filer)
- INSIDERSEC Form 4: York Michael sold $44,331 worth of shares (107,054 units at $0.41), decreasing direct ownership by 51% to 103,499 units (tax withholding)4 - Metacrine, Inc. (0001634379) (Issuer)
- INSIDERSEC Form 4: Klassen Preston sold $157,266 worth of shares (380,605 units at $0.41), decreasing direct ownership by 41% to 541,905 units (tax withholding)4 - Metacrine, Inc. (0001634379) (Issuer)
- NEWSMetacrine Says President, CEO, Secretary, Principal Executive Officer Preston Klassen Was Terminated From Positions, Effective Feb. 1-Reuters
- SECSEC Form PRE 14A filed by Metacrine Inc.PRE 14A - Metacrine, Inc. (0001634379) (Filer)
- SECMetacrine Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits8-K - Metacrine, Inc. (0001634379) (Filer)
- NEWSMetacrine, Equillium And 3 Stocks To Watch Heading Into TuesdayWith US stock futures trading higher this morning on Friday, some of the stocks that may grab investor focus today are as follows: Metacrine, Inc. (NASDAQ:MTCR) and Equillium, Inc. (NASDAQ:EQ) mutually agreed to terminate definitive merger agreement. Metacrine shares jumped 5.4% to $0.4551 in after-hours trading, while Equillium shares dropped 6.3% to close at $0.89 on Friday. Oragenics, Inc. (NYSE:OGEN) disclosed a 1-for-60 reverse stock split. Oragenics shares dipped 6.7% to close at $0.1450 on Friday. Check out our premarket coverage here Pintec Technology Holdings Limited (NASDAQ:PT) reported that its total revenues dropped by 56.53% year-over-year to RMB39.82 million ($5.93 mi
- NEWSMetacrine Shares Resume Trade Following Circuit Breaker Halt, Stock Now Up 14%
- SECMetacrine Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits8-K - Metacrine, Inc. (0001634379) (Filer)
- NEWSMetacrine and Equillium Mutually Agree to Terminate Definitive Merger AgreementMetacrine, Inc. (NASDAQ:MTCR) and Equillium, Inc. today announced the mutual termination of their previously announced definitive merger agreement. Metacrine is continuing to evaluate all strategic opportunities. Additional information regarding the termination of the definitive merger agreement is provided set forth in a Current Report on Form 8-K filed by Metacrine with the U.S. Securities and Exchange Commission today and is available at www.sec.gov and on Metacrine's website under the heading "Investors."
MTCR FAQ
8 questionsWhat does Metacrine Inc. do?
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with liver and gastrointestinal diseases. It is developing MET409 that has completed Phase 1b proof-of-concept clinical trial for the treatment of patients with non-alcoholic steatohepatitis (NASH); and is in Phase 2a clinical trial in combination with empagliflozin for the treatment of patients with type 2 diabetes mellitus and NASH. The company also develops MET642, which is in Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis patients...What is the latest news on MTCR?
Quantisnow has not tracked any new filings, ratings or press releases for MTCR in the last 30 days. The most recent wire item was published on March 24, 2023.Where does MTCR stock trade?
Metacrine Inc. (MTCR) is listed on NASDAQ.What sector and industry is MTCR in?
Metacrine Inc. operates in the Health Care sector, Medicinal Chemicals and Botanical Products industry.When did Metacrine Inc. go public?
Metacrine Inc. (MTCR) completed its IPO in 2020.What are analysts saying about MTCR?
Across the last 4 analyst actions on Metacrine Inc., there were 0 upgrades and 4 downgrades. The most recent action was from RBC Capital Mkts: Sector Perform with a $2.50 price target on 2021-10-22. Recent price targets range from $1.00 to $2.50.What companies are similar to MTCR?
Notable peers in the same industry include SMFL (Smart for Life Inc.), VLON (Vallon Pharmaceuticals Inc.), MNMD (Mind Medicine (MindMed) Inc.), GRPH (Graphite Bio Inc.), SISI (Shineco Inc.). Compare MTCR side-by-side with any of them on Quantisnow.How can I track MTCR on Quantisnow?
Quantisnow aggregates Metacrine Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MTCR to receive live email and push alerts on every new disclosure.